resectable pancreatic cancer
Showing 1 - 22 of 22
Resectable Pancreatic Cancer Trial in Denmark (ctDNA)
Recruiting
- Resectable Pancreatic Cancer
- ctDNA
-
Aalborg, Denmark
- +4 more
Mar 27, 2023
Resectable Pancreatic Cancer Trial in Tianjin (AG Followed by FOLFIRINOX)
Recruiting
- Resectable Pancreatic Cancer
- AG Followed by FOLFIRINOX
-
Tianjin, Tianjin, ChinaRui Liu
Jan 8, 2023
Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
Terminated
- Pancreatic Adenocarcinoma
- +2 more
- Germline genetic testing
-
San Francisco, CaliforniaInvitae SF
Dec 5, 2022
Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer Trial (Nab paclitaxel, Gemcitabine, NovoTTF-200T)
Not yet recruiting
- Pancreatic Adenocarcinoma
- Resectable Pancreatic Cancer
- Nab paclitaxel
- +2 more
- (no location specified)
Dec 5, 2022
Resectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas Trial in Ulm (perioperative nab-paclitaxel/gemcitabine,
Completed
- Resectable Pancreatic Cancer
- Ductal Adenocarcinoma of the Pancreas
- perioperative nab-paclitaxel/gemcitabine
- adjuvant nab-paclitaxel/gemcitabine
-
Ulm, GermanyUniversity of Ulm, Dept. of Internal Medicine I
Nov 21, 2022
Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma Trial in Boston (drug,
Not yet recruiting
- Pancreatic Cancer
- +3 more
- mFOLFIRINOX
- +7 more
-
Boston, Massachusetts
- +1 more
Sep 16, 2022
Pancreas Adenocarcinoma, Resectable Pancreatic Cancer Trial in Loma Linda (Gemcitabine 1000 mg, nab-paclitaxel, Stereotactic
Recruiting
- Pancreas Adenocarcinoma
- Resectable Pancreatic Cancer
- Gemcitabine 1000 mg
- +2 more
-
Loma Linda, CaliforniaLoma Linda University Health
Jun 14, 2022
Resectable Pancreatic Cancer Trial in Toulouse (Blood samples)
Recruiting
- Resectable Pancreatic Cancer
- Blood samples
-
Toulouse, FranceUniversity Hospital
Mar 15, 2022
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma Trial in Scottsdale (Paclitaxel Protein
Active, not recruiting
- Resectable Pancreatic Cancer
- +3 more
- Paclitaxel Protein Bound (Abraxane)
-
Scottsdale, ArizonaHonorHealth Research Institute
Feb 15, 2022
Resectable Pancreatic Cancer Trial in Seoul (intraoperative radiotherapy, IORT)
Recruiting
- Resectable Pancreatic Cancer
- intraoperative radiotherapy, IORT
-
Seoul, Korea, Republic ofGangnam Severance Hospital
Jan 3, 2022
Resectable Pancreatic Cancer Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Recruiting
- Resectable Pancreatic Cancer
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Nov 15, 2021
Cancer of Pancreas, Pancreas Adenocarcinoma, Resectable Pancreatic Cancer Trial in Pavia (Preoperative chemo, Preoperative
Recruiting
- Cancer of Pancreas
- +2 more
- Preoperative chemotherapy
- Preoperative radiotherapy
-
Pavia, ItalyCNAO
Aug 31, 2021
Resectable Pancreatic Cancer Trial in Canada (Modified Folforinox (mFFX))
Recruiting
- Resectable Pancreatic Cancer
- Modified Folforinox (mFFX)
-
Vancouver, British Columbia, Canada
- +7 more
Jun 24, 2021
Pancreatic Cancer, Resectable Pancreatic Cancer Trial in Tampa (Pimonidazole, Surgical Resection)
Withdrawn
- Pancreatic Cancer
- Resectable Pancreatic Cancer
- Pimonidazole
- Surgical Resection
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Feb 3, 2021
Resectable Pancreatic Cancer, Adjuvant Chemoradiotherapy, Surgery Trial in Shanghai (other, drug, radiation)
Recruiting
- Resectable Pancreatic Cancer
- +2 more
- Follow-up only
- +3 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital Fudan University
Feb 1, 2021
Resectable Pancreatic Cancer Trial in Craiova, Bucharest, Cluj Napoca
Completed
- Resectable Pancreatic Cancer
-
Craiova, Dolj, Romania
- +4 more
Apr 26, 2020
Resectable Pancreatic Cancer Trial in Baltimore (Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85
Completed
- Resectable Pancreatic Cancer
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable
- +3 more
-
Baltimore, MarylandUniversity of Maryland Medical Center
Aug 15, 2019
Resectable Pancreatic Cancer Trial (NGC-Triple regimen)
Withdrawn
- Resectable Pancreatic Cancer
- NGC-Triple regimen
- (no location specified)
May 3, 2019
Pancreatic Adenocarcinoma, Poorly Differentiated Malignant Tumor, Resectable Pancreatic Cancer Trial in Cleveland (Irinotecan
Terminated
- Pancreatic Adenocarcinoma
- +8 more
- Irinotecan Hydrochloride
- +4 more
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jun 13, 2018
Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma Trial in Boston (FOLFIRINOX, Gemcitabine/nab-Paclitaxel, Radiation
Terminated
- Resectable Pancreatic Cancer
- Pancreatic Ductal Carcinoma
- FOLFIRINOX
- +3 more
-
Boston, MassachusettsMassachusetts General Hospital
Apr 10, 2017
Resectable Pancreatic Cancer Trial in United States (Gemcitabine and Abraxane)
Completed
- Resectable Pancreatic Cancer
- Gemcitabine and Abraxane
-
Scottsdale, Arizona
- +3 more
Jun 15, 2015
Resectable Pancreatic Cancer Trial in New Brunswick (LDE-225)
Withdrawn
- Resectable Pancreatic Cancer
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Dec 10, 2014